Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 4 records in total 4
    records per page




    Frequency and severity of Covid-19 in patients treated with biological Disease MESHD Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD. A case-control study

    Authors: Dr. Anne LOHSE; Dr. Marie BOSSERT; Dr. Ana-Maria BOZGAN; Charlotte BOURGOIN; Dr. Aline CHARPENTIER; Dr. Cerise GUILLOCHON; Dr. Julie KESSLER; Dr. Jean-Charles BALBLANC; Dr. Thierry CONROZIER

    doi:10.21203/rs.3.rs-50490/v1 Date: 2020-07-29 Source: ResearchSquare

    The aim of the study was to assess the impact (frequency and severity) of Covid-19 on patients treated with biological Disease MESHD Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD and to compare it to a control group consisting of patients with musculoskeletal conditions not treated with bDMARDs.Patients and methods:A case control study in 200 outpatients with musculoskeletal conditions. 100 consecutive patients who have been treated with bDMARDs and 100 other consecutive patients who did not take bDMARDs were asked to complete a 15-item standardized questionnaire regarding demographic data. The following information was recorded: gender TRANS, age TRANS, weight, height, body mass index, professional activity, family status, total number of children TRANS and number of children TRANS under 18, rheumatic disease MESHD diagnosis, current treatment for rheumatism, type of containment, close contact TRANS with Covid-19 patients, Covid-19 symptoms, Covid-19 test result and hospitalization for Covid-19.Results:bDMARD patients mostly suffered from rheumatoid arthritis MESHD rheumatoid arthritis HP, or RA, (47%) and ankylosing spondylitis MESHD (42%). The most prescribed bDMARDs were TNFα inhibitors (57%), IL-6 blockers (12%) and JAK inhibitors (11%). The mean duration of the current biological treatment was 38.6 months. Patients from the control group were suffering chiefly from osteoarthritis MESHD osteoarthritis HP (45%) and RA (21%). Compared to the control group, patients treated with bDMARDs were 10 years younger (p<0.001), fewer were retired (56% versus 31%) and more were on sick or incapacity leave (6% versus 18%). During lockdown, they were more likely to be working from home or working short term (27% versus 9%). 18 patients from the bDMARDs group stopped biological treatment: one because of Covid-19 evidenced by PCR, 11 because of symptoms suggesting Covid- 19 and only six from fear of contracting the disease MESHD. 12 patients, including the one Sars-CoV-2 +, resumed their treatment after a few weeks of interruption. There was no severe Covid-19 infection MESHD in the bDMARDs group. Among the three patients from the control group who had contracted Covid-19, one developed a very severe disease MESHD.Conclusion :This case-control study did not show an increase in the frequency or severity of Covid-19 in subjects suffering from chronic inflammatory rheumatism treated with biotherapies. Larger-scale studies are necessary before affirming that biologics do not expose patients to an increased risk of disease MESHD and complications.

    C-C chemokine receptor type 5 links COVID-19, Rheumatoid arthritis MESHD Rheumatoid arthritis HP, and Hydroxychloroquine

    Authors: Mahmood Yaseen Hachim; Ibrahim Hachim; Kashif Naeem; Haifa Hannawi; Issa Al Salmi; Suad Hannawi

    doi:10.21203/rs.3.rs-48001/v1 Date: 2020-07-23 Source: ResearchSquare

    Background: Patients with rheumatoid arthritis MESHD rheumatoid arthritis HP (RA) represent one of the fragile patient groups that might be susceptible to coronavirus disease MESHD -19 (COVID-19) and its severe form. On the other side, RA patients have been found not to have an increased risk of COVID19 infection MESHD. Moreover, some of the Disease MESHD-Modifying Anti-Rheumatic Drugs (DMARDS)  commonly used to treat rheumatic diseases MESHD like Hydroxychloroquine (HCQ) were proposed as a potential therapy for COVID19 with a lack of full understanding of their molecular mechanisms. This highlights the need for the discovery of common pathways that may link both diseases MESHD at the molecular side Methods: We used the in silico approach to investigate the transcriptomic profile of RA synovium compared to osteoarthritis MESHD osteoarthritis HP and healthy controls to identify RA specific molecular pathways shared with that of severe acute respiratory syndrome MESHD-corona virus-2 (SARS-COV-2) infected lung tissue. Results: Our results showed upregulation of chemotactic factors, including CCL4, CCL8, and CCL11, that all shared CCR5 as their receptor, as a common derangement observed in both diseases MESHD; RA and COVID-19. Moreover, our results also highlighted that HCQ might interfere with the COVID-19 infection MESHD through its ability to upregulate specific immune cell populations like activated natural killer (NK) cells, besides blocking CCR5 rich immune cell recruitment to the SARS-COV-2 infected lungs Conclusion: Our results might explain some of the reports that showed beneficial effects and indicate the need for proper patients stratification on their immune profile before selecting the therapeutic protocol or clinical trial enrollment. Keyword COVID-19, SARS-COV-2, Hydroxychloroquine, rheumatoid arthritis MESHD rheumatoid arthritis HP

    Factors Associated with Hospitalization and Disease MESHD Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients

    Authors: Angelico Mendy; Senu Apewokin; Anjanette A Wells; Ardythe L Morrow

    doi:10.1101/2020.06.25.20137323 Date: 2020-06-26 Source: medRxiv

    Background: The coronavirus disease MESHD (COVID-19) first identified in Wuhan in December 2019 became a pandemic within a few months of its discovery. The impact of COVID-19 is due to both its rapid spread and its severity, but the determinants of severity have not been fully delineated. Objective: Identify factors associated with hospitalization and disease MESHD severity in a racially and ethnically diverse cohort of COVID-19 patients. Methods: We analyzed data from COVID-19 patients diagnosed at the University of Cincinnati health system from March 13, 2020 to May 31, 2020. Severe COVID-19 was defined as admission to intensive care unit or death MESHD. Logistic regression modeling adjusted for covariates was used to identify the factors associated with hospitalization and severe COVID-19. Results: Among the 689 COVID-19 patients included in our study, 29.2% were non-Hispanic White, 25.5% were non-Hispanic Black, 32.5% were Hispanic, and 12.8% were of other race/ethnicity. About 31.3% of patients were hospitalized and 13.2% had severe disease MESHD. In adjusted analyses, the sociodemographic factors associated with hospitalization and/or disease MESHD severity included older age TRANS, non-Hispanic Black or Hispanic race/ethnicity (compared to non-Hispanic White), and smoking. The following comorbidities: diabetes, hypercholesterolemia MESHD hypercholesterolemia HP, asthma MESHD asthma HP, COPD, chronic kidney disease HP kidney disease MESHD, cardiovascular diseases MESHD, osteoarthritis MESHD osteoarthritis HP, and vitamin D deficiency MESHD were associated with hospitalization and/or disease MESHD severity. Hematological disorders such as anemia MESHD anemia HP, coagulation disorders, and thrombocytopenia MESHD thrombocytopenia HP were associated with both hospitalization and disease MESHD severity. Conclusion: This study confirms race and ethnicity as predictors of severe COVID-19. It also finds clinical risk factors for hospitalization and severe COVID-19 not previously identified such a vitamin D deficiency MESHD, hypercholesterolemia MESHD hypercholesterolemia HP, osteoarthritis MESHD osteoarthritis HP, and anemia MESHD anemia HP.

    C-C Chemokine Receptor Type 5 Links COVID-19, Rheumatoid Arthritis MESHD Rheumatoid Arthritis HP, and Hydroxychloroquine

    Authors: Mahmood Yaseen HACHIM; Ibrahim Y. Hachim; Kashif Naeem; Haifa Hannawi; Issa Al Salmi; Suad Hannawi

    doi:10.21203/rs.3.rs-37404/v1 Date: 2020-06-22 Source: ResearchSquare

    Background: Patients with rheumatoid arthritis MESHD rheumatoid arthritis HP (RA) represent one of the fragile patient groups that might be susceptible to coronavirus disease MESHD -19 (COVID-19) and its severe form. On the other side, RA patients have been found not to have an increased risk of COVID19 infection MESHD. Moreover, some of the Disease MESHD-Modifying Anti-Rheumatic Drugs (DMARDS)  commonly used to treat rheumatic diseases MESHD like Hydroxychloroquine (HCQ) were proposed as a potential therapy for COVID19 with a lack of full understanding of their molecular mechanisms. This highlights the need for the discovery of common pathways that may link both diseases MESHD at the molecular side Methods: We used the in silico approach to investigate the transcriptomic profile of RA synovium compared to osteoarthritis MESHD osteoarthritis HP and healthy controls to identify RA specific molecular pathways shared with that of severe acute respiratory syndrome MESHD-corona virus-2 (SARS-COV-2) infected lung tissue. Results: Our results showed upregulation of chemotactic factors, including CCL4, CCL8, and CCL11, that all shared CCR5 as their receptor, as a common derangement observed in both diseases MESHD; RA and COVID-19. Moreover, our results also highlighted that HCQ might interfere with the COVID-19 infection MESHD through its ability to upregulate specific immune cell populations like activated natural killer (NK) cells, besides blocking CCR5 rich immune cell recruitment to the SARS-COV-2 infected lungs Conclusion: Our results might explain some of the reports that showed beneficial effects and indicate the need for proper patients stratification on their immune profile before selecting the therapeutic protocol or clinical trial enrollment. Keyword COVID-19, SARS-COV-2, Hydroxychloroquine, rheumatoid arthritis MESHD rheumatoid arthritis HP

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.